Literature DB >> 17416848

The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?

Beth Y Karlan, Martin McIntosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17416848     DOI： 10.1200/JCO.2006.09.7543

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Authors:  Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-01       Impact factor: 4.254

3.  Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

Authors:  Archana Raamanathan; Glennon W Simmons; Nicolaos Christodoulides; Pierre N Floriano; Wieslaw B Furmaga; Spencer W Redding; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.